Also the advancing of radiologically visible destructions caused by the rheumatic disease is apparently stopped. This was confirmed by the results of a study (REFLEX-randomised evaluation of long-term efficacy of rituximab in RA) that were introduced at the annual convention of the American College of Rheumatology. The licence for the German market has already been applied for, so there is a prospect of help for patients with severe rheumatism.
